Phase II Study of Weekly Irinotecan and Carboplatin in Extensive-Stage Small-Cell Lung Cancer
- Determine the response rate in patients with newly diagnosed, previously untreated
extensive stage small cell lung cancer treated with irinotecan and carboplatin.
- Determine the progression-free and overall survival of patients treated with this
OUTLINE: This is a multicenter study.
Patients receive irinotecan IV and carboplatin IV on days 1 and 8. Treatment repeats every
21 days for 6 courses.
PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Tadashi Mio, MD
United States: Federal Government